Related Experiment Videos
Activation of human monocyte-derived macrophages cultured on Teflon: response to interferon-gamma during terminal
R Andreesen1, S Gadd, W Brugger
1Medizinische Klinik, Universität Freiburg i. Brsg. Federal Republic of Germany.
Abstract:
Macrophages (M phi) are potential antitumor effector cells derived from circulating blood monocytes (mo). Most studies on human mo/M phi biology and function have been performed using immature mo precursor cells. However, the conclusions drawn may be questionable, as mo have to undergo terminal differentiation before they reach relevant tissue sites of inflammation and immune reaction. We have analyzed the ability of mo-derived, teflon-cultured M phi to respond to activating stimuli with an increased tumor cytotoxic effector cell function using recombinant interferon-gamma (IFN-gamma), IFN-alpha 2, granulocyte/macrophage colony stimulating factor (GM-CSF), interleukin(IL) 2, IL 1 alpha, and bacterial lipopolysaccharides (LPS) as mediator molecules. It could be shown that the response of M phi to the most potent activator molecule, IFN-gamma, depends on the terminal differentiation from the mo stage to the mature M phi. Whereas adherent mo could be activated only moderately, M phi increased their cytotoxicity by a factor of up to 400. IFN-gamma activation positively correlated with the effector cell number, the time of incubation and the dosage used. Activation did not depend on the presence of LPS, and was lost within 24 to 48 h. LPS itself activated cells only in the microgram range. IFN-alpha 2 activated M phi only at a two log higher concentration than IFN-gamma; GM-CSF was only slightly effective, whereas M phi incubation with IL 1 alpha or IL 2 did not result in M phi activation. Thus, the ability of human M phi to become activated appears to be a function of cellular maturation and is acquired during the terminal step of M phi differentiation. Teflon-cultured M phi could facilitate studies of the activation of human M phi and may be more suitable cells for adoptive immunotherapy in cancer patients than blood monocytes.
Insights
Mature macrophages, not monocytes, effectively fight tumors when activated by interferon-gamma. This cellular maturation is key for developing effective cancer immunotherapies.
Area of Science:
- Immunology
- Cell Biology
- Cancer Research
Background:
- Macrophages (M phi) are crucial antitumor effector cells derived from monocytes (mo).
- Previous studies often used immature monocyte precursors, potentially yielding misleading functional data.
- Monocytes require terminal differentiation into macrophages to become effective in tissue environments.
Purpose of the Study:
- To investigate the activation potential of teflon-cultured, differentiated macrophages (M phi) compared to monocytes (mo).
- To assess the tumor cytotoxic effector function of M phi in response to various activating stimuli.
- To determine the role of cellular maturation in macrophage activation.
Main Methods:
- Human monocytes were cultured to differentiate into macrophages (M phi) using teflon culture.
- Differentiated M phi and adherent monocytes were exposed to activating agents: interferon-gamma (IFN-gamma), IFN-alpha 2, GM-CSF, IL-2, IL-1 alpha, and LPS.
- Tumor cytotoxic effector function was measured following stimulation.
Main Results:
- Interferon-gamma (IFN-gamma) significantly enhanced M phi cytotoxicity by up to 400-fold, dependent on differentiation.
- Monocyte activation by IFN-gamma was moderate, while M phi showed substantial increases in cytotoxicity.
- Activation efficacy varied among stimuli: IFN-gamma was most potent, followed by IFN-alpha 2 and GM-CSF; IL-1 alpha and IL-2 were ineffective. LPS showed weak activation at high concentrations.
Conclusions:
- Macrophage (M phi) activation and enhanced tumor cytotoxicity are dependent on cellular maturation from the monocyte (mo) stage.
- Teflon-cultured M phi exhibit superior responsiveness to activating stimuli like IFN-gamma compared to monocytes.
- Mature M phi are more promising candidates for adoptive immunotherapy in cancer patients than blood monocytes.